MRNA

No open position. Record a trade on the Portfolio tab and it flows into this card.

Moderna's post-pandemic transition shows revenue heavily concentrated in COVID vaccines, exceeding 40% of total. The company has generated multiple new EDGAR filings (10-K, 10-Qs, 8-K) providing updates on financials and operations. Leverage is low, and cash position remains strong, so balance sheet distress is not a concern at this stage.

Generated by deepseek-v4-flash. Advisory only — every flag is logged against the rule that raised it for the review loop.

• 10-QMay 01, 2026

  Source ↗

  Moderna's Q1 2026 results reflect strong revenue growth from international COVID vaccine deliveries under long-term government partnerships, but the bottom line was heavily impacted by a $878 million litigation settlement charge related to Arbutus/Genevant. Excluding this, operating expenses declined due to disciplined cost management. The company maintains a solid balance sheet with $7.4 billion in equity and $590 million in debt, though a potential $1.3 billion additional payment from the Arbutus appeal remains a key risk. Guidance points to revenue growth in 2026, stable to lower cost of sales (ex-settlement), and continued expense discipline. Strategic priorities center on advancing the pipeline (mCOMBRIAX approval, intismeran data, norovirus), partnerships, and IP resolution, while capital allocation is constrained by debt covenants. The outlook is cautiously positive on top-line expansion but tempered by legal uncertainties and seasonal demand patterns.

  Show extraction ▾Hide extraction ▴

  MD&A highlights

  • ·Total revenue for Q1 2026 was $389 million, up 260% from $108 million in Q1 2025, driven by a 309% increase in net product sales to $352 million, primarily from international COVID vaccine deliveries under long-term government partnerships.
  • ·Net loss was $(1,343) million, or $(3.40) per share, compared to $(971) million, or $(2.52) per share in the prior year; the increase was largely due to an $878 million litigation settlement charge recorded in cost of sales.
  • ·Cost of sales was $955 million, including $895 million in third-party royalties (of which $878 million related to the Arbutus/Genevant settlement), $38 million in inventory write-downs, and amortization of the associated intangible asset.
  • ·Research and development expenses decreased 24% to $649 million, driven by lower clinical manufacturing costs, reduced consulting, and lower headcount.
  • ·Selling, general and administrative expenses decreased 18% to $173 million, reflecting cost discipline and streamlined operations.
  • ·As of March 31, 2026, the company had three commercial products (Spikevax, mNEXSPIKE, mRESVIA) and received EU marketing authorization for mCOMBRIAX in April 2026.

  Guidance

  Product sales are expected to return to growth in 2026, supported by the full-year impact of long-term strategic partnerships with government entities. Cost of sales, excluding the Arbutus/Genevant settlement, is anticipated to remain at a relatively consistent level compared to 2025, with continued manufacturing productivity improvements. Research and development expenses are expected to see a modest reduction in 2026 compared to 2025, driven by portfolio prioritization and disciplined cost management. Selling, general and administrative expenses are expected to remain relatively consistent with 2025.

  Debt / leverage

  As of March 31, 2026, the company had $590 million in long-term debt (net of discount and issuance costs) under a $1.5 billion senior secured credit agreement with Ares Capital, consisting of a $600 million initial term loan (interest rate ~9.17%) and $900 million of undrawn delayed draw commitments. The company was in compliance with all covenants, including a minimum cash requirement of $500 million (or $750 million if more than $1.0 billion is drawn) unless the trailing 30-day market capitalization exceeds $5.0 billion.

  Key risks

  • ·Potential additional payment of up to $1.3 billion related to the Arbutus/Genevant settlement appeal, which could materially impact financial condition.
  • ·Ongoing patent litigation with Pfizer/BioNTech, GSK, Northwestern University, and others, which could affect commercial products and pipeline.
  • ·Dependence on seasonal demand for respiratory vaccines, with higher sales expected in fall/winter.
  • ·Execution risks in R&D pipeline, including clinical trial enrollment, regulatory approvals, and commercialization.
  • ·Manufacturing and supply chain risks, including reliance on third-party suppliers and internal capacity.
  • ·Intellectual property challenges and royalty obligations that could impact cost of sales.
  • ·Need for additional financing to support operations and debt service; the credit agreement includes restrictive covenants.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  Product sales are expected to return to growth in 2026, supported by the full-year impact of long-term strategic partnerships with government entities. We anticipate a modest reduction in research and development expenses in 2026 compared to 2025, driven by continued portfolio prioritization, disciplined cost management, and a focused approach to pipeline execution. We expect selling, general and administrative expenses in 2026 to remain at a level relatively consistent with 2025, reflecting an efficient and scalable operating structure.

  Strategic priorities

  • ·Advance the mRNA pipeline across infectious disease vaccines, oncology therapeutics, and rare disease therapeutics.
  • ·Execute strategic collaborations, including the Recordati partnership for propionic acidemia (mRNA-3927) and the Mexico government agreement for local manufacturing.
  • ·Deliver cost efficiency through portfolio prioritization, disciplined cost management, and streamlined operations.
  • ·Secure regulatory approvals and commercial launches for key products, including mCOMBRIAX in the EU and mRNA-1010 seasonal flu vaccine.
  • ·Resolve intellectual property disputes, as demonstrated by the Arbutus/Genevant settlement, to provide certainty for the infectious disease portfolio.
  • ·Advance late-stage pipeline programs, including intismeran autogene (individualized neoantigen therapy) with Merck and the norovirus vaccine candidate.

  Capital allocation

  As of March 31, 2026, $1.7 billion remained available under the 2022 share repurchase program, with no shares repurchased during the quarter. The company did not pay dividends. Capital allocation priorities include funding operations, R&D, and debt service; the credit agreement restricts certain payments including dividends and share repurchases subject to covenants.

  Risk-factor changes

  No material changes to risk factors from the 2025 Form 10-K, except the new risk associated with the Arbutus/Genevant settlement appeal, which could require an additional payment of up to $1.3 billion depending on the outcome.

  Extracted by deepseek-v4-flash · Jul 23, 2026

• 8-KMay 01, 2026Item 2.02,9.01

  Source ↗

  This 8-K filing by Moderna, Inc. on May 1, 2026, merely furnishes a press release (Exhibit 99.1) announcing first quarter 2026 financial results. The filing itself contains no quantitative or qualitative details beyond the incorporation of that press release. No MD&A highlights, guidance, backlog, debt commentary, key risks, capex plans, strategic priorities, outlook, risk factor changes, or capital allocation information are provided in the 8-K body. Analysts would need to review the attached press release for substantive content.

  Show extraction ▾Hide extraction ▴

  Extracted by deepseek-v4-flash · Jul 23, 2026

• 8-KMar 05, 2026Item 1.01unprocessed

  Source ↗

  Facts ingested; qualitative extraction pending.

• 10-KFeb 20, 2026

  Source ↗

  Moderna's 2025 10-K depicts a company navigating the post-pandemic landscape: revenue of $1.9B (mostly COVID vaccines) with net losses, but management forecasts 2026 growth underpinned by long-term government partnerships and mNEXSPIKE adoption. The pipeline shows promise—intismeran autogene (melanoma) with sustained efficacy data, and several late-stage vaccine candidates (flu, combo, norovirus) approaching potential launches. Operational discipline is a focus, with cost reduction plans and manufacturing capacity expansions underway. Risks include regulatory uncertainty, intense competition, reliance on market acceptance, and continued financial losses. Capital allocation policy is not disclosed; no dividends or buybacks are mentioned. The outlook is cautiously optimistic, grounded in platform breadth but tempered by execution and competitive headwinds.

  Show extraction ▾Hide extraction ▴

  MD&A highlights

  • ·Total revenue of $1.9 billion in 2025, largely from sales of COVID vaccines.
  • ·mNEXSPIKE launched commercially in Q3 2025; now leading product in U.S. retail channel.
  • ·Phase 2b study of intismeran autogene (mRNA-4157) with Merck showed 49% reduction in recurrence risk at 5 years in high-risk melanoma.
  • ·mRNA-1010 influenza vaccine BLA accepted by FDA with PDUFA date August 5, 2026; regulatory filings also in Europe, Canada, Australia.
  • ·mRNA-1083 (flu+COVID combination) under regulatory review in Europe and Canada.
  • ·mRNA-3927 for propionic acidemia reached target enrollment in registrational study; strategic collaboration with Recordati in January 2026.
  • ·CEPI agreed to invest up to $54.3 million for Phase 3 trial of pandemic flu vaccine mRNA-1018.
  • ·Marlborough facility for intismeran began clinical batch supply in September 2025.
  • ·Manufacturing facilities in UK, Canada, Australia fully licensed in 2025 with multi-year government purchase commitments.

  Guidance

  Management expects revenue growth in 2026 from the annualized impact of long-term partnerships in the UK, Canada, and Australia, as well as continued strong uptake of mNEXSPIKE in the U.S. They anticipate further cost reductions in 2026 and 2027, leveraging global production network, AI, and digital tools. Multiple new product launches (flu, flu+COVID combination, norovirus) are expected over the next few years.

  Backlog

  Multi-year purchase commitments from the governments of the UK, Canada, and Australia for mRNA products from local manufacturing facilities, which were fully licensed in 2025.

  Debt / leverage

  Project financing from Blackstone Life Sciences supports the flu vaccine development; a secured term loan facility exists but details are not fully described in the excerpt.

  Key risks

  • ·Regulatory and market uncertainty impacting business and product markets.
  • ·Difficulties executing near-term strategy and prioritized pipeline.
  • ·Intense competition in vaccine and pharmaceutical markets.
  • ·Commercial challenges and dependence on market acceptance and reimbursement.
  • ·Lengthy and uncertain clinical development; potential delays or termination.
  • ·Dependence on single-source suppliers for components and materials.
  • ·Inability to obtain and enforce patent protection; intellectual property litigation.
  • ·Net losses in 2025 and 2024, with expectation of additional losses; limited history of profitability.
  • ·Cybersecurity risks and potential breaches of internal systems.

  Forward-looking · richest in 10-Ks

  Outlook / tone

  Management expresses a cautiously optimistic outlook, stating 'We expect to drive revenue growth in 2026' and 'We believe that the development of mRNA medicines represents a significant breakthrough,' while acknowledging 'We incurred net losses in 2025 and 2024, and expect to incur additional losses in the future.' The tone is confident in the platform's potential but pragmatic about near-term financial challenges and competitive dynamics.

  Strategic priorities

  • ·Deliver sales growth through geographic expansion and new product launches.
  • ·Deliver cost efficiency across the business via manufacturing, R&D, and SG&A improvements.
  • ·Execute on our prioritized pipeline with pivotal data readouts and product launches.
  • ·Continue to advance our early pipeline and platform technology across modalities.

  Capex / expansion

  Construction began in 2025 at the MTC campus for new commercial drug product manufacturing and packaging capability; Marlborough facility completed for intismeran clinical supply; international facilities in UK, Canada, Australia fully licensed in 2025.

  Risk-factor changes

  The summary of material risks emphasizes execution of near-term strategy and commercial challenges, reflecting the transition from pandemic-driven demand to an endemic and pipeline-dependent model. New risks include difficulties in executing the prioritized pipeline and commercial challenges in a competitive market.

  Extracted by deepseek-v4-flash · Jul 23, 2026

• 8-KFeb 13, 2026Item 2.02,9.01unprocessed

  Source ↗

  Facts ingested; qualitative extraction pending.

No signals for this name.